NEW YORK (GenomeWeb News) – BD Diagnostics, a segment of Becton Dickinson, today announced that the US Food and Drug Administration has cleared the BD Max MRSA molecular test for marketing in the US.

The assay runs on the fully automated BD Max System and was developed to rapidly identify patients with methicillin-resistant Staphylococcus aureus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.